Annual CFF
-$18.45 M
+$4.93 M+21.09%
31 December 2023
Summary:
Core Laboratories NV annual cash flow from financing activities is currently -$18.45 million, with the most recent change of +$4.93 million (+21.09%) on 31 December 2023. During the last 3 years, it has risen by +$44.56 million (+70.72%). CLB annual CFF is now -117.89% below its all-time high of $103.10 million, reached on 31 December 1997.CLB Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$8.83 M
+$4.85 M+35.46%
30 September 2024
Summary:
Core Laboratories NV quarterly cash flow from financing activities is currently -$8.83 million, with the most recent change of +$4.85 million (+35.46%) on 30 September 2024. Over the past year, it has dropped by -$2.84 million (-47.41%). CLB quarterly CFF is now -111.72% below its all-time high of $75.30 million, reached on 30 June 1997.CLB Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
-$45.06 M
-$2.84 M-6.72%
30 September 2024
Summary:
Core Laboratories NV TTM cash flow from financing activities is currently -$45.06 million, with the most recent change of -$2.84 million (-6.72%) on 30 September 2024. Over the past year, it has dropped by -$32.52 million (-259.38%). CLB TTM CFF is now -143.71% below its all-time high of $103.10 million, reached on 31 December 1997.CLB TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CLB Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +21.1% | -47.4% | -259.4% |
| 3 y3 years | +70.7% | +62.2% | -83.7% |
| 5 y5 years | +56.6% | +50.4% | +55.3% |
CLB Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +70.7% | -245.6% | +62.2% | -267.6% | at low |
| 5 y | 5 years | at high | +78.5% | -224.6% | +63.4% | -267.6% | +55.3% |
| alltime | all time | -117.9% | +93.0% | -111.7% | +91.8% | -143.7% | +85.6% |
Core Laboratories NV Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$8.83 M(-35.5%) | -$45.06 M(+6.7%) |
| June 2024 | - | -$13.68 M(+235.2%) | -$42.22 M(+47.7%) |
| Mar 2024 | - | -$4.08 M(-77.9%) | -$28.59 M(+55.0%) |
| Dec 2023 | -$18.45 M(-21.1%) | -$18.48 M(+208.6%) | -$18.45 M(+47.1%) |
| Sept 2023 | - | -$5.99 M(>+9900.0%) | -$12.54 M(+2.3%) |
| June 2023 | - | -$42.00 K(-100.7%) | -$12.26 M(-23.0%) |
| Mar 2023 | - | $6.06 M(-148.2%) | -$15.93 M(-31.9%) |
| Dec 2022 | -$23.38 M(+4.1%) | -$12.57 M(+120.2%) | -$23.38 M(+49.8%) |
| Sept 2022 | - | -$5.71 M(+53.9%) | -$15.61 M(-53.1%) |
| June 2022 | - | -$3.71 M(+168.0%) | -$33.27 M(+7.6%) |
| Mar 2022 | - | -$1.38 M(-71.2%) | -$30.93 M(+37.7%) |
| Dec 2021 | -$22.46 M(-64.4%) | -$4.81 M(-79.4%) | -$22.46 M(-8.4%) |
| Sept 2021 | - | -$23.37 M(+1609.4%) | -$24.53 M(-3.0%) |
| June 2021 | - | -$1.37 M(-119.3%) | -$25.29 M(-37.7%) |
| Mar 2021 | - | $7.08 M(-203.0%) | -$40.58 M(-35.6%) |
| Dec 2020 | -$63.01 M(-26.6%) | -$6.88 M(-71.5%) | -$63.01 M(-15.2%) |
| Sept 2020 | - | -$24.13 M(+44.9%) | -$74.33 M(+9.3%) |
| June 2020 | - | -$16.66 M(+8.6%) | -$68.01 M(-16.4%) |
| Mar 2020 | - | -$15.34 M(-15.7%) | -$81.36 M(-5.3%) |
| Dec 2019 | -$85.87 M(+102.2%) | -$18.20 M(+2.2%) | -$85.87 M(-14.8%) |
| Sept 2019 | - | -$17.81 M(-40.6%) | -$100.78 M(+86.0%) |
| June 2019 | - | -$30.00 M(+51.0%) | -$54.18 M(+26.9%) |
| Mar 2019 | - | -$19.86 M(-40.0%) | -$42.70 M(+0.5%) |
| Dec 2018 | -$42.47 M(-59.2%) | -$33.11 M(-215.0%) | -$42.47 M(-13.9%) |
| Sept 2018 | - | $28.79 M(-255.5%) | -$49.35 M(-52.2%) |
| June 2018 | - | -$18.52 M(-5.7%) | -$103.22 M(+3.1%) |
| Mar 2018 | - | -$19.63 M(-50.9%) | -$100.15 M(-3.8%) |
| Dec 2017 | -$104.08 M(-16.7%) | -$39.99 M(+59.5%) | -$104.08 M(+21.7%) |
| Sept 2017 | - | -$25.08 M(+62.4%) | -$85.52 M(-3.0%) |
| June 2017 | - | -$15.45 M(-34.4%) | -$88.20 M(-11.4%) |
| Mar 2017 | - | -$23.56 M(+9.9%) | -$99.55 M(-20.3%) |
| Dec 2016 | -$124.90 M(-30.7%) | -$21.43 M(-22.8%) | -$124.90 M(-13.1%) |
| Sept 2016 | - | -$27.76 M(+3.6%) | -$143.72 M(-8.1%) |
| June 2016 | - | -$26.79 M(-45.2%) | -$156.31 M(+2.5%) |
| Mar 2016 | - | -$48.91 M(+21.5%) | -$152.44 M(-15.5%) |
| Dec 2015 | -$180.30 M(-31.5%) | -$40.26 M(-0.2%) | -$180.30 M(-21.5%) |
| Sept 2015 | - | -$40.35 M(+76.1%) | -$229.68 M(-11.5%) |
| June 2015 | - | -$22.92 M(-70.1%) | -$259.59 M(-8.2%) |
| Mar 2015 | - | -$76.77 M(-14.4%) | -$282.90 M(+7.5%) |
| Dec 2014 | -$263.12 M(+5.6%) | -$89.64 M(+27.6%) | -$263.12 M(+6.7%) |
| Sept 2014 | - | -$70.26 M(+52.0%) | -$246.71 M(+2.5%) |
| June 2014 | - | -$46.24 M(-18.9%) | -$240.78 M(-4.1%) |
| Mar 2014 | - | -$56.98 M(-22.2%) | -$251.07 M(+0.8%) |
| Dec 2013 | -$249.08 M(+16.8%) | -$73.23 M(+13.8%) | -$249.08 M(-3.1%) |
| Sept 2013 | - | -$64.33 M(+13.8%) | -$257.07 M(+10.4%) |
| June 2013 | - | -$56.52 M(+2.8%) | -$232.75 M(+7.4%) |
| Mar 2013 | - | -$54.99 M(-32.3%) | -$216.70 M(+1.6%) |
| Dec 2012 | -$213.30 M(-16.9%) | -$81.22 M(+103.0%) | -$213.30 M(+29.7%) |
| Sept 2012 | - | -$40.02 M(-1.1%) | -$164.52 M(+7.0%) |
| June 2012 | - | -$40.47 M(-21.6%) | -$153.75 M(-23.5%) |
| Mar 2012 | - | -$51.60 M(+59.0%) | -$200.99 M(-21.7%) |
| Dec 2011 | -$256.66 M(+19.8%) | -$32.44 M(+10.9%) | -$256.66 M(-10.3%) |
| Sept 2011 | - | -$29.25 M(-66.7%) | -$286.05 M(-8.6%) |
| June 2011 | - | -$87.70 M(-18.2%) | -$313.08 M(+34.7%) |
| Mar 2011 | - | -$107.27 M(+73.5%) | -$232.50 M(+8.5%) |
| Dec 2010 | -$214.26 M | -$61.83 M(+9.9%) | -$214.26 M(+55.4%) |
| Sept 2010 | - | -$56.28 M(+690.4%) | -$137.87 M(+36.1%) |
| June 2010 | - | -$7.12 M(-92.0%) | -$101.27 M(+3.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2010 | - | -$89.03 M(-711.7%) | -$97.48 M(+429.0%) |
| Dec 2009 | -$18.43 M(-82.2%) | $14.55 M(-174.0%) | -$18.43 M(-79.5%) |
| Sept 2009 | - | -$19.68 M(+490.9%) | -$89.97 M(-6.8%) |
| June 2009 | - | -$3.33 M(-66.6%) | -$96.54 M(+2.0%) |
| Mar 2009 | - | -$9.97 M(-82.5%) | -$94.69 M(-8.6%) |
| Dec 2008 | -$103.58 M(-22.9%) | -$56.98 M(+117.0%) | -$103.58 M(+16.6%) |
| Sept 2008 | - | -$26.25 M(+1678.8%) | -$88.83 M(-14.9%) |
| June 2008 | - | -$1.48 M(-92.2%) | -$104.36 M(-7.6%) |
| Mar 2008 | - | -$18.86 M(-55.3%) | -$112.96 M(-15.9%) |
| Dec 2007 | -$134.33 M(+138.9%) | -$42.24 M(+1.1%) | -$134.33 M(+64.0%) |
| Sept 2007 | - | -$41.78 M(+314.6%) | -$81.93 M(+32.5%) |
| June 2007 | - | -$10.08 M(-75.0%) | -$61.84 M(-19.3%) |
| Mar 2007 | - | -$40.23 M(-496.2%) | -$76.61 M(+36.2%) |
| Dec 2006 | -$56.23 M(-7.4%) | $10.15 M(-146.8%) | -$56.23 M(-32.9%) |
| Sept 2006 | - | -$21.69 M(-12.7%) | -$83.83 M(-1.9%) |
| June 2006 | - | -$24.84 M(+25.2%) | -$85.49 M(+15.6%) |
| Mar 2006 | - | -$19.85 M(+13.8%) | -$73.98 M(+21.9%) |
| Dec 2005 | -$60.70 M(+0.6%) | -$17.44 M(-25.3%) | -$60.70 M(+8.8%) |
| Sept 2005 | - | -$23.35 M(+75.1%) | -$55.81 M(+27.8%) |
| June 2005 | - | -$13.34 M(+102.9%) | -$43.67 M(-25.3%) |
| Mar 2005 | - | -$6.57 M(-47.6%) | -$58.47 M(-3.1%) |
| Dec 2004 | -$60.33 M(+175.3%) | -$12.55 M(+11.9%) | -$60.33 M(+0.8%) |
| Sept 2004 | - | -$11.21 M(-60.1%) | -$59.83 M(+5.7%) |
| June 2004 | - | -$28.14 M(+234.0%) | -$56.59 M(+121.8%) |
| Mar 2004 | - | -$8.43 M(-30.1%) | -$25.52 M(+16.4%) |
| Dec 2003 | -$21.91 M(+43.7%) | -$12.05 M(+51.1%) | -$21.91 M(+17.4%) |
| Sept 2003 | - | -$7.97 M(-371.6%) | -$18.66 M(+66.0%) |
| June 2003 | - | $2.94 M(-160.8%) | -$11.24 M(-41.6%) |
| Mar 2003 | - | -$4.83 M(-45.2%) | -$19.26 M(+26.3%) |
| Dec 2002 | -$15.25 M(-205.4%) | -$8.80 M(+1487.9%) | -$15.25 M(+60.8%) |
| Sept 2002 | - | -$554.00 K(-89.1%) | -$9.48 M(-281.9%) |
| June 2002 | - | -$5.08 M(+523.7%) | $5.21 M(-65.9%) |
| Mar 2002 | - | -$815.00 K(-73.1%) | $15.27 M(+5.6%) |
| Dec 2001 | $14.46 M(-5.8%) | -$3.03 M(-121.4%) | $14.46 M(+4.5%) |
| Sept 2001 | - | $14.14 M(+184.3%) | $13.84 M(+880.5%) |
| June 2001 | - | $4.97 M(-405.8%) | $1.41 M(-92.4%) |
| Mar 2001 | - | -$1.63 M(-55.4%) | $18.47 M(+20.4%) |
| Dec 2000 | $15.35 M(-434.8%) | -$3.65 M(-313.0%) | $15.35 M(-613.6%) |
| Sept 2000 | - | $1.71 M(-92.2%) | -$2.99 M(+23.1%) |
| June 2000 | - | $22.04 M(-563.5%) | -$2.43 M(-83.2%) |
| Mar 2000 | - | -$4.75 M(-78.4%) | -$14.45 M(+215.2%) |
| Dec 1999 | -$4.58 M(-139.7%) | -$21.98 M(-1066.7%) | -$4.58 M(-117.1%) |
| Sept 1999 | - | $2.27 M(-77.3%) | $26.73 M(+20.1%) |
| June 1999 | - | $10.02 M(+96.0%) | $22.26 M(+22.0%) |
| Mar 1999 | - | $5.11 M(-45.2%) | $18.24 M(+58.2%) |
| Dec 1998 | $11.53 M(-88.8%) | $9.33 M(-524.2%) | $11.53 M(-21.6%) |
| Sept 1998 | - | -$2.20 M(-136.7%) | $14.70 M(-11.4%) |
| June 1998 | - | $6.00 M(-475.0%) | $16.60 M(-80.7%) |
| Mar 1998 | - | -$1.60 M(-112.8%) | $85.90 M(-16.7%) |
| Dec 1997 | $103.10 M(<-9900.0%) | $12.50 M(-4266.7%) | $103.10 M(+15.8%) |
| Sept 1997 | - | -$300.00 K(-100.4%) | $89.00 M(+1.1%) |
| June 1997 | - | $75.30 M(+382.7%) | $88.00 M(+645.8%) |
| Mar 1997 | - | $15.60 M(-1075.0%) | $11.80 M(-1785.7%) |
| Dec 1996 | -$700.00 K(-116.7%) | -$1.60 M(+23.1%) | -$700.00 K(-177.8%) |
| Sept 1996 | - | -$1.30 M(+44.4%) | $900.00 K(-59.1%) |
| June 1996 | - | -$900.00 K(-129.0%) | $2.20 M(-29.0%) |
| Mar 1996 | - | $3.10 M | $3.10 M |
| Dec 1995 | $4.20 M | - | - |
FAQ
- What is Core Laboratories NV annual cash flow from financing activities?
- What is the all time high annual CFF for Core Laboratories NV?
- What is Core Laboratories NV annual CFF year-on-year change?
- What is Core Laboratories NV quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Core Laboratories NV?
- What is Core Laboratories NV quarterly CFF year-on-year change?
- What is Core Laboratories NV TTM cash flow from financing activities?
- What is the all time high TTM CFF for Core Laboratories NV?
- What is Core Laboratories NV TTM CFF year-on-year change?
What is Core Laboratories NV annual cash flow from financing activities?
The current annual CFF of CLB is -$18.45 M
What is the all time high annual CFF for Core Laboratories NV?
Core Laboratories NV all-time high annual cash flow from financing activities is $103.10 M
What is Core Laboratories NV annual CFF year-on-year change?
Over the past year, CLB annual cash flow from financing activities has changed by +$4.93 M (+21.09%)
What is Core Laboratories NV quarterly cash flow from financing activities?
The current quarterly CFF of CLB is -$8.83 M
What is the all time high quarterly CFF for Core Laboratories NV?
Core Laboratories NV all-time high quarterly cash flow from financing activities is $75.30 M
What is Core Laboratories NV quarterly CFF year-on-year change?
Over the past year, CLB quarterly cash flow from financing activities has changed by -$2.84 M (-47.41%)
What is Core Laboratories NV TTM cash flow from financing activities?
The current TTM CFF of CLB is -$45.06 M
What is the all time high TTM CFF for Core Laboratories NV?
Core Laboratories NV all-time high TTM cash flow from financing activities is $103.10 M
What is Core Laboratories NV TTM CFF year-on-year change?
Over the past year, CLB TTM cash flow from financing activities has changed by -$32.52 M (-259.38%)